C000010380 Performance — Biotechnology Fund, Variable Annuity
Data updated: 2026-08-21
C000010380 returned +18.90% year to date and +57.40% over one year to Jun 2026. Annualised returns are +18.11% over 3 years and +5.52% over 5 years. The fund beat its Health Care Equity category average: $100 invested three years ago grew to $165, against $138 for the category, and to $157 over one year, against $137. Volatility over the past three years was 17.11% a year. In the 12 months to Jun 2026 the fund lost a net $192K, and assets reached $13.48M.
C000010380 Growth of $100
What $100 invested in Biotechnology Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | C000010380 | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $157 | $137 |
| 3 years (Jul 2023 – Jun 2026) | $165 | $138 |
| 5 years (Jul 2021 – Jun 2026) | $131 | $121 |
| Since data start (Jul 2019 – Jun 2026) | $188 | $182 |
C000010380 Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +18.90% |
| 1 year | +57.40% |
| 3 years (annualised) | +18.11% |
| 5 years (annualised) | +5.52% |
C000010380 Annual Returns
Calendar-year total returns of Biotechnology Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +18.90% |
| 2025 | +30.12% |
| 2024 | −1.40% |
| 2023 | +5.53% |
| 2022 | −13.31% |
| 2021 | +1.42% |
| 2020 | +21.31% |
| 2019 (Jul–Dec) | +9.31% |
C000010380 Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.1% | +2.2% | −2.5% | +0.9% | +4.7% | +10.6% | — | — | — | — | — | — |
| 2025 | +5.3% | −0.2% | −6.2% | +0.3% | −3.6% | +3.2% | +4.1% | +4.9% | +5.4% | +8.8% | +8.1% | −2.1% |
| 2024 | −1.3% | +2.2% | −0.1% | −7.3% | +5.0% | +4.6% | +6.0% | +1.7% | −2.8% | −1.5% | +1.1% | −7.8% |
| 2023 | +2.2% | −4.5% | +0.1% | +1.8% | −2.6% | +0.9% | +0.9% | −0.5% | −4.3% | −6.1% | +6.1% | +12.9% |
| 2022 | −10.4% | −3.1% | +3.8% | −10.0% | −0.3% | 0.0% | +5.2% | −3.6% | −3.5% | +7.8% | +6.4% | −4.3% |
| 2021 | +5.2% | −2.1% | −4.5% | +4.3% | −3.4% | +9.2% | −1.6% | +3.7% | −5.3% | +0.2% | −4.5% | +1.2% |
| 2020 | −7.4% | 0.0% | −7.9% | +15.8% | +9.0% | +1.5% | +0.3% | −0.4% | +0.4% | −2.7% | +10.5% | +3.1% |
| 2019 | — | — | — | — | — | — | −3.4% | −3.8% | −1.6% | +6.7% | +12.2% | −0.2% |
C000010380 Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 17.11%
- 3-year Sharpe ratio: 0.80 (vs 4.5% risk-free rate)
- Best month: +12.93% (Dec 2023)
- Worst month: −7.78% (Dec 2024)
C000010380 Fund Flows
Monthly money in and out of Biotechnology Fund, from SEC Form N-PORT.
- 12-month net flow: −$192K
- 12-month gross sales (incl. reinvestments): $28.7M
- Sales ÷ redemptions: 0.99×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $9.9M | $10.0M | −$24K |
| May 2026 | $8.0M | $9.9M | −$1.9M |
| Apr 2026 | $6.9M | $4.3M | $2.6M |
| Mar 2026 | $27K | $684K | −$656K |
| Feb 2026 | $146K | $436K | −$291K |
| Jan 2026 | $117K | $352K | −$235K |
| Dec 2025 | $409K | $1.3M | −$940K |
| Nov 2025 | $1.1M | $375K | $719K |
| Oct 2025 | $1.0M | $474K | $537K |
| Sep 2025 | $149K | $270K | −$121K |
| Aug 2025 | $369K | $370K | −$922 |
| Jul 2025 | $531K | $437K | $95K |
C000010380 Assets Under Management
Net assets of Biotechnology Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $13.48M |
| 2026-03-31 | $10.67M |
| 2025-12-31 | $11.66M |
| 2025-09-30 | $9.83M |
| 2025-06-30 | $9.00M |
| 2025-03-31 | $9.41M |
| 2024-12-31 | $9.98M |
| 2024-09-30 | $11.04M |
| 2024-06-30 | $10.97M |
| 2024-03-31 | $11.79M |
| 2023-12-31 | $12.20M |
| 2023-09-30 | $11.55M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.